Advanced Sarcoma
9
2
3
2
Key Insights
Highlights
Success Rate
50% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 87/100
22.2%
2 terminated out of 9 trials
50.0%
-36.5% vs benchmark
0%
0 trials in Phase 3/4
50%
1 of 2 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 2 completed trials
Clinical Trials (9)
A Precision Medicine Approach (SMMART-ACT) for the Treatment of Patients With Advanced Sarcoma, Prostate, Breast, Ovarian or Pancreatic Cancer
Lenvatinib and Pembrolizumab in People With Advanced Soft Tissue Sarcoma
At-Home Cancer Directed Therapy Versus in Clinic for the Treatment of Patients With Advanced Cancer
Effects of a Neuroscience-based Technique on Cancer Patients Announced of a Palliative Disease Progression and Partners
Study of DCC-3014 in Combination With Avelumab in Patients With Advanced or Metastatic Sarcomas
A Phase I Trial of Memory T Cells Expressing an NKG2D Chimeric Antigen Receptor in Children, Adolescents and Young Adults With Advanced Sarcoma
SMMART Adaptive Clinical Treatment (ACT) Trial
YH001 Plus Envafolimab With or Without Doxorubicin in Patients With Advanced or Metastatic Sarcoma
Study of ZIO-201 in Advanced Sarcoma